Mechanisms of NSAID-induced hepatotoxicity focus on nimesulide

Drug Safety

Volumn 25, Issue 9, 2002, Pages 633-648

  Boelsterli, Urs A ^a,b  

^a HepaTox Consulting   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

COVALENT BOND; DISEASE ACTIVITY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; DRUG STRUCTURE; HEPATOBILIARY SYSTEM; HEREDITY; HUMAN; INCIDENCE; INFLAMMATION; INTRAHEPATIC CHOLESTASIS; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; OXIDATIVE STRESS; PAIN; PRIORITY JOURNAL; REACTION ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ANALYSIS;

EID: 0036051341     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225090-00003     Document Type: Review

References (122)

1. Cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs in humans: Ex vivo evaluation
2. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide
3. Adverse drug reactions related to the use of NSA1Ds with a focus on nimesulide: Results of spontaneous reporting from a Northern Italian area
4. Topical nonsteroidal anti-inflammatory drugs: Allergic and photoallergic contact dermatitis and phototoxicity
5. Liver disease produced by non-steroidal anti-inflammatory drugs
6. Hepatic injury associated with nonsteroidal anti-inflammatory drugs
7. Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: Molecular mechanisms and pathology
8. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: New insights into an old problem
9. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system
10. Adverse effects of non-steroidal anti-inflammatory drugs on the small and large bowel
11. Detection and prevention of NSAID-induced enteropathy
12. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis
13. Mechanisms underlying the hepatotoxicity of nonsteroidal anti-inflammatory drugs
14. Hepatotoxicity of analgesics and anti-inflammatory agents
15. Incidence of hepatitis induced by non-steroidal anti-inflammatory drugs (NSAID)
16. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs
17. Genetic susceptibility to adverse drug reactions
18. New concepts in immunology relevant to idiosyncratic drug reactions: The 'danger hypothesis' and innate immune system
19. Mechanisms of liver cell injury
20. FDA Arthritis Advisory Committee Meeting
21. The mechanism of inhibition of mitochondrial oxidative phosphorylation by the non-steroidal anti-inflammatory agent diflunisal
22. The effects of ibuprofen enantiomers on hepatocyte intermediary metabolism and mitochondrial respiration
23. Uncoupling effects of diclofenac and aspirin in the perfused liver and isolated hepatic mitochondria of rat
24. Structural requirements for the hepatotoxicity of nousteroidal anti-inflammatory drugs in isolated rat hepatocytes
25. Stereoselective and substrate-dependent inhibition of hepatic mitochondrial β-oxidation and oxidative phosphorylation by the non-steroidal anti-inflammatory drugs ibuprofen, flurbiprofen, and ketorolac
26. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs
27. The mitochondrial permeability transition in toxic, hypoxic and reperfusion injury
28. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria
29. Ibuprofen-induced liver mitochondrial permeability transition
30. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs
31. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2)
32. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats
33. Hepatic disposition of electrophilic acyl glucuronide conjugates
34. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver
35. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism?
36. Predictability of the covalent binding of acidic drugs in man
37. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac
38. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma
39. Immunochemical identification of mouse hepatic protein adducts derived from the non-steroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen
40. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver
41. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: Possible role in allergic reactions
42. Reactive acyl glucuronides: Possible role in small intestinal toxicity induced by nonsteroidal anti-inflammatory drugs
43. Drug enterocyte adducts: Possible causal factors for diclofenac enteropathy in rats
44. Acyl glucuronides in idiosyncratic toxicity
45. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac
46. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system
47. Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro
48. Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenac
49. Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats
50. Hypersensitivity to nonsteroidal anti-inflammatory drugs
51. Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats
52. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice
53. Cytokine pathways and joint inflammation in rheumatoid arthritis
54. 4-Nitro-2-phenoxymethane sulfoanilide (R-805): A chemically novel antiinflammatory agent
55. Non-steroidal anti-inflammatories - XII: Mode of action of anti-inflammatory methane sulfonanilides
56. Nimesulide: A selective cyclooxygenase 2 inhibitor anti-inflammatory drug
57. Overview of nimesulide
58. Molecular model of the interaction between nimesulide and human cyclooxygenase-2
59. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity
60. Nimesulide: An NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities
61. Interaction between NSAIDs and steroid in rat stomach: Safety of nimesulide as a preferential COX-2 inhibitor in the stomach
62. Nimesulide: A well-established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases
63. Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV
64. An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury
65. Hepatitis-like syndrome induced by nimesulide [case report]
66. Hepatotoxicity associated with nimesulide
67. Nimesulide-induced acute hepatitis: Evidence from six cases
68. COX 2 inhibitor and fulminant hepatic failure
69. Acute cholestatic hepatitis induced by nimesulide
70. Nimesulide-induced hepatitis and acute liver failure
71. Fatal hepatitis associated with nimesulide
72. Fatal hepatitis and renal failure during treatment with nimesulide
73. Comparison of two clinical scales for causality assessment in hepatotoxicity
74. Fatal hepatotoxicity secondary to nimesulide
75. Nimesulide-induced acute hepatitis
76. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union
77. Underreporting of adverse drug reactions: Estimate based on a spontaneous reporting scheme and a sentinel system
78. Epidemiological assessment of drug-induced disease
79. Drug-induced liver disorders: Implications for drug development and regulation
80. Drug hepatotoxicity
81. Nimesulide: An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
82. Advances in molecular toxicology: Towards understanding idiosyncratic drug toxicity
83. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide
84. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide: Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes
85. Antioxidant and cyto-protective properties of D-tagatose in cultured murine hepatocytes
86. Characterization of furazolidine apical-related effects to human polarized intestinal cells
87. Nitroreduction of nitrated and C-9 oxidized fluorenes in vitro
88. The mechanism of microsomal and mitochondrial nitroreductase: Electron spin resonance evidence for nitroaromatic free radical intermediates
89. Electrochemical generation and interaction study of the nitro anion from nimesulide
90. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: Implications for idiosyncratic toxicity
91. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
92. Clinical pharmacokinetics of nimesulide
93. Effects of nimesulide and its reduced metabolite on mitochondria
94. The uncoupling effect of the nonsteroidal anti-inflammatory drug nimesulide in liver mitochondria from adjuvant-induced arthritic rats
95. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in the rat
96. Tumor necrosis factor α in the pathogenesis of human and murine fulminant hepatic failure
97. Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP
98. Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing tumor necrosis factor
99. Nimesulide prevents lipopolysaccharide-induced elevation in plasma tumor necrosis factor-α in rats
100. A cellular rescue team
101. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
102. Acetyltransferases
103. Arylamine N-acetyl-transferases: Of mice, men and microorganisms
104. The drug hypersensitivity syndrome: What is the pathogenesis?
105. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes
106. Electrochemical, UV-visible and EPR studies on nitrofurantoin: Nitro anion radical generation and its interaction with glutathione
107. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes
108. An electrochemical evidence of free radicals formation from flutamide and its reactivity with endo/xenobiotics of pharmacological relevance
109. Synthesis and reactions of nitroso sulfamethoxazole with biological nucleophiles: Implications for immune-mediated toxicity
110. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat
111. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer
112. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors
113. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccaride-stimulated human peripheral blood mononuclear cells
114. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release
115. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: The effect of nimesulide compared with naproxen on the human gastrointestinal tract
116. Does nimesulide induce gastric mucosal damage? A double-blind randomized placebo-controlled trial
117. In vivo selectivity of nonsteroidal anti-inflammatory drugs and gastrointestinal ulcers in rats
118. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen
119. Relationship of nimesulide safety to its pharmacokinetics: Assessment of adverse reactions